

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**Study Number:**

**Study Gender:**

**PWG Approval Date:**

**Version:**

**M04: Hematology**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

I10482

Female

See web page for date of PWG Approval

v1.0.9

**Date Report Requested:** 11/04/2020

**Time Report Requested:** 14:06:54

**Lab:** Burleson Research Technologies

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

M04: Hematology

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/04/2020

Time Report Requested: 14:06:54

Lab: Burlison Research Technologies

Females: Immunopath

Treatment Groups (ppm)

	0	313	625	1250	2500
Erythrocyte (x10 <sup>6</sup> )	9.793 ± 0.166 (8)	9.664 ± 0.138 (8)	9.622 ± 0.101 (8)	9.770 ± 0.054 (8)	9.725 ± 0.076 (8)
Hemoglobin (g/dL)	15.88 ± 0.13 (8)	15.60 ± 0.11 (8)	15.50 ± 0.16 (8)	15.89 ± 0.14 (8)	15.68 ± 0.06 (8)
Hematocrit (%)	52.15 ± 0.96 (8) *	52.18 ± 0.98 (8)	52.60 ± 0.57 (8)	53.85 ± 0.47 (8)	53.74 ± 0.70 (8)
MCV (fL)	53.29 ± 0.71 (8) **	53.98 ± 0.49 (8)	54.68 ± 0.21 (8) *	55.09 ± 0.23 (8) **	55.24 ± 0.41 (8) *
MCH (pg)	16.24 ± 0.33 (8)	16.14 ± 0.19 (8)	16.10 ± 0.07 (8)	16.25 ± 0.08 (8)	16.11 ± 0.08 (8)
MCHC (g/dL)	30.48 ± 0.52 (8) **	29.90 ± 0.52 (8)	29.46 ± 0.07 (8)	29.51 ± 0.23 (8)	29.20 ± 0.27 (8) **
Platelets (x10 <sup>3</sup> )	795.8 ± 23.9 (8) **	763.4 ± 27.4 (8)	710.0 ± 29.7 (8)	760.3 ± 46.7 (8)	905.1 ± 17.0 (8)
Leukocyte (x10 <sup>3</sup> )	6.32 ± 0.60 (8)	5.41 ± 0.47 (8)	5.66 ± 0.50 (8)	5.42 ± 0.55 (8)	6.39 ± 0.48 (8)
Reticulocytes (x10 <sup>3</sup> )	227.95 ± 32.48 (8)	258.39 ± 10.94 (8)	248.79 ± 12.87 (8)	236.03 ± 15.24 (8)	246.61 ± 14.93 (8)
Percent Reticulocytes	2.309 ± 0.297 (8)	2.669 ± 0.095 (8)	2.580 ± 0.122 (8)	2.416 ± 0.158 (8)	2.539 ± 0.158 (8)

**Study Number:** I10482  
**Test Type:** TOX  
**Route:** Dosing in Feed  
**Species/Strain:** Mouse/B6C3F1/N

**M04: Hematology**  
**Test Compound:** N-Butylbenzenesulfonamide  
**CAS Number:** 3622-84-2

**Date Report Requested:** 11/04/2020  
**Time Report Requested:** 14:06:54  
**Lab:** Burleson Research Technologies

---

<b>Females: Immunopath</b>		
<b>Treatment Groups (ppm)</b>		
	<b>5000</b>	<b>50 mg/kg CPS</b>
Erythrocyte (x10 <sup>6</sup> )	9.683 ± 0.096 (8)	8.540 ± 0.082 (8) **
Hemoglobin (g/dL)	15.58 ± 0.12 (8)	13.63 ± 0.13 (8) **
Hematocrit (%)	53.95 ± 0.60 (8)	46.73 ± 0.50 (8) **
MCV (fL)	55.74 ± 0.35 (8) **	54.71 ± 0.26 (8)
MCH (pg)	16.06 ± 0.10 (8)	15.96 ± 0.10 (8)
MCHC (g/dL)	28.85 ± 0.20 (8) **	29.18 ± 0.22 (8) *
Platelets (x10 <sup>3</sup> )	859.6 ± 25.9 (8)	1059.9 ± 37.9 (8) **
Leukocyte (x10 <sup>3</sup> )	4.50 ± 0.09 (8)	1.69 ± 0.21 (8) **
Reticulocytes (x10 <sup>3</sup> )	247.88 ± 13.31 (8)	57.01 ± 5.04 (8) **
Percent Reticulocytes	2.561 ± 0.135 (8)	0.666 ± 0.057 (8) **

---

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**M04: Hematology**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 11/04/2020

**Time Report Requested:** 14:06:54

**Lab:** Burleson Research Technologies

#### LEGEND

---

Data are displayed as mean  $\pm$  SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

MCV - mean corpuscular volume; MCH - mean corpuscular hemoglobin; MCHC - mean corpuscular hemoglobin concentration

CPS = Cyclophosphamide

**\*\* END OF REPORT \*\***